Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-Tuberculosis Lung Disease: The Role of Surgical Management.

Thoracic surgery clinics·2026
Same author

Surgery for Active and Drug-Resistant Tuberculosis.

Thoracic surgery clinics·2026
Same author

Worldwide Impact of Human Development and Inequality on the Prevalence of Asthma, Rhinoconjunctivitis and Eczema. Global Asthma Network's Ecological Study.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Environmental risk factors for allergic rhinitis differ by income level: A Global Asthma Network survey.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

Update on Tuberculosis Treatment and Drug Regimens.

Cold Spring Harbor perspectives in medicine·2026
Same author

World TB Day 2026: Scientific innovation across the tuberculosis continuum must now translate into global impact.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same journal

High-Flow Nasal Oxygen in Early Home Pulmonary Rehabilitation for Exertional Hypoxaemia: A Pilot Randomised Feasibility Trial.

Respirology (Carlton, Vic.)·2026
Same journal

Contemporary Concise Review 2025: Asthma.

Respirology (Carlton, Vic.)·2026
Same journal

Early Intervention With Biologics for Asthma Remission: Promising or Premature?

Respirology (Carlton, Vic.)·2026
Same journal

Clinical and Inflammatory Phenotypes During Exacerbations Predict In-Hospital Adverse Outcomes in Asthma-COPD Overlap.

Respirology (Carlton, Vic.)·2026
Same journal

Diagnostic Yield of EBUS Mediastinal Cryobiopsy Versus TBNA in Suspected Lymphoproliferative Disorders: A Prospective Multicentre Study.

Respirology (Carlton, Vic.)·2026
Same journal

Association of Airway Mucus Plugs and Physical Activity, Exercise Tolerance, Sarcopenia, and Frailty in Patients With COPD and Pre-COPD.

Respirology (Carlton, Vic.)·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Drug-resistant tuberculosis: past, present, future.

Chen-Yuan Chiang1, Rosella Centis, Giovanni Battista Migliori

  • 1Department of Lung Health and NCDs, International Union Against Tuberculosis and Lung Disease, Paris, France.

Respirology (Carlton, Vic.)
|March 27, 2010
PubMed
Summary
This summary is machine-generated.

Drug-resistant tuberculosis (TB) emerges from mutations, with multi-drug-resistant TB (MDR-TB) affecting 1.6% of new and 11.7% of treated cases globally. Preventing resistance is crucial to avoid widespread extensively drug-resistant TB (XDR-TB).

Related Experiment Videos

Last Updated: Jun 14, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Genetics

Background:

  • Tuberculosis (TB) resistance to anti-TB drugs arises from chromosomal mutations.
  • Drug resistance in Mycobacterium tuberculosis strains is a growing global health concern.
  • Multi-drug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant treatment challenges.

Purpose of the Study:

  • To present global data on anti-TB drug resistance, focusing on MDR-TB and XDR-TB prevalence.
  • To discuss treatment strategies and challenges for drug-resistant TB.
  • To highlight the importance of preventing further drug resistance.

Main Methods:

  • Analysis of global anti-TB drug resistance data from the fourth report.
  • Review of treatment guidelines and challenges for MDR-TB and XDR-TB.
  • Modeling exercise to predict XDR-TB prevalence based on treatment and detection rates.

Main Results:

  • Median MDR-TB prevalence is 1.6% in new cases and 11.7% in previously treated cases.
  • An estimated 50% of half a million MDR-TB cases in 2006 were in China and India.
  • Optimal treatment durations for MDR-TB and XDR-TB are undefined; second-line drug susceptibility testing reliability is questionable.
  • Modeling suggests XDR-TB could increase exponentially if detection/treatment rates rise without improved cure rates.

Conclusions:

  • Drug-resistant TB is not necessarily less virulent.
  • Prevention of drug resistance development must be a top priority.
  • Effective strategies for MDR-TB and XDR-TB treatment and prevention are urgently needed.